Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW42003:GW42004 in Olanzapine-Induced Weight Gain
NCT01491490Phase 2Terminated
- Sponsor
- GW Pharmaceuticals
- Start
- Oct 2011
- Primary completion
- Oct 2012
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cannabidiol, tetrahydrocannabivarin in dyslipidemia, sponsored by GW Pharmaceuticals. Started Oct 2011; status: terminated.
02
Drugs
cannabidioltetrahydrocannabivarin
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT01491490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01491490.